Compound ID | 92
Class: Drug combination: beta-lactam (cephalosporin) + beta-lactamase inhibitor
Spectrum of activity: | Gram-positive & Gram-negative |
Details of activity: | Bacterial infections including gram-negative. Complicated urinary tract infections, complicated intra-abdominal infections, acute pyelonephritis (kidney infection), hospital-acquired bacterial pneumonia/ ventilator-associated bacterial pneumonia |
Combined with other compounds: | Yes |
Institute where first reported: | Pfizer Inc./Allergan PLC (formerly Actavis) |
Year first mentioned: | 2005 |
Highest developmental phase: | Approved by FDA in 2015 |
Development status: | Approved |
Chemical structure(s): | |
Ceftazidime | |
Canonical SMILES: | CC(C)(C(=O)O)O/N=C(/C1=CSC(=N1)N)\C(=O)N[C@@H]2C(=O)N3C(=C(C[N+]4=CC=CC=C4)CS[C@H]23)C(=O)[O-] |
Isomeric SMILES: | CC(C)(C(=O)O)O/N=C(/C1=CSC(=N1)N)\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4=CC=CC=C4)C(=O)[O-] |
InChI: | InChI=1S/C22H22N6O7S2/c1-22(2,20(33)34)35-26-13(12-10-37-21(23)24-12)16(29)25-14-17(30)28-15(19(31)32)11(9-36-18(14)28)8-27-6-4-3-5-7-27/h3-7,10,14,18H,8-9H2,1-2H3,(H4-,23,24,25,29,31,32,33,34)/b26-13-/t14-,18-/m1/s1 |
InChI Key: | ORFOPKXBNMVMKC-DWVKKRMSSA-N |
Avibactam | |
Canonical SMILES: | C1C[C@@H](C(=O)N)N2C[C@@H]1N(C2=O)OS(=O)(=O)O |
Isomeric SMILES: | C1C[C@H](N2C[C@@H]1N(C2=O)OS(=O)(=O)O)C(=O)N |
InChI: | InChI=1S/C7H11N3O6S/c8-6(11)5-2-1-4-3-9(5)7(12)10(4)16-17(13,14)15/h4-5H,1-3H2,(H2,8,11)(H,13,14,15)/t4-,5+/m1/s1 |
InChI Key: | NDCUAPJVLWFHHB-UHNVWZDZSA-N |